Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples